Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed)
Open
National Institutes of Health is offering grants of up to $2.0 million to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expects to make about 5 awards worth $15.0 million in total. Applications close on December 14, 2026.
From the official notice on Grants.gov, last changed October 9, 2026. Checked October 31, 2026.
- Award ceiling$2.0 million
- Award floornot stated
- Expected awards5
- Total funding$15.0 million
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | October 9, 2026 |
|---|---|
| Deadline | December 14, 2026 |
| Archived by Grants.gov | February 14, 2027 |
Add the deadline to your calendar
Who can apply
This opportunity is open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/Foreign CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards. Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications to characterize genomic variation to assess the impact of individual variants on genome function. This will be accomplished by systematically perturbing variants or elements using one or more high-throughput methods; collecting data on the effects of variants in DNA, RNA, or protein-coding elements on molecular, cellular, or organismal phenotypes; and developing robust, reproducible, and portable data processing pipelines. Centers funded through this initiative will become a part of the Impact of Genomic Variation on Function (IGVF) Consortium. As consortium members, centers will work together to ensure all consortium resources are accessible to a wide variety of potential users. Centers are also expected to collaborate with other consortium components to coordinate assays, variants, and cell types, and to develop shared analysis strategies to meet consortium goals.
How to apply
- Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
- Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
- Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.
Questions go to National Institutes of Health, nhgri-igvf@mail.nih.gov, 301-402-2541.
Questions people ask
Who can apply for Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed)?
National Institutes of Health accepts applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed)?
Closes December 14, 2026 (44 days left). Confirm the date and time in the official notice on Grants.gov.
How much funding is available?
Awards of up to $2.0 million each. About $15.0 million in total across about 5 awards.
Similar open grants
- Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
- BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE)
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
- Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
- Exposomic Contributions to ADRD Pathology and Resilience